Potential new targets and drugs related to histone modifications in glioma treatment
| Autor: | Lanlan Zang, Fengyuan Che, Liying Wang, Bolian Xiao, Xiuhong Wei |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Antineoplastic Agents
Drug action 01 natural sciences Biochemistry Histones Glioma Drug Discovery medicine Temozolomide Humans Clinical significance neoplasms Molecular Biology biology 010405 organic chemistry Mechanism (biology) Chemistry Brain Neoplasms Standard treatment Organic Chemistry medicine.disease nervous system diseases 0104 chemical sciences 010404 medicinal & biomolecular chemistry Histone Acetylation Drug Resistance Neoplasm biology.protein Cancer research medicine.drug DNA Damage |
| Zdroj: | Bioorganic chemistry. 112 |
| ISSN: | 1090-2120 |
| Popis: | Glioma accounts for 40-50% of craniocerebral tumors, whose outcome rarely improves after standard treatment. The development of new therapeutic targets for glioma treatment has important clinical significance. With the deepening of research on gliomas, recent researchers have found that the occurrence and development of gliomas is closely associated with histone modifications, including methylation, acetylation, phosphorylation, and ubiquitination. Additionally, evidence has confirmed the close relationship between histone modifications and temozolomide (TMZ) resistance. Therefore, histone modification-related proteins have been widely recognized as new therapeutic targets for glioma treatment. In this review, we summarize the potential histone modification-associated targets and related drugs for glioma treatment. We have further clarified how histone modifications regulate the pathogenesis of gliomas and the mechanism of drug action, providing novel insights for the current clinical glioma treatment. Herein, we have also highlighted the limitations of current clinical therapies and have suggested future research directions and expected advances in potential areas of disease prognosis. Due to the complicated glioma pathogenesis, in the present review, we have acknowledged the limitations of histone modification applications in the related clinical treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect